IMBDX Posts Subscription Competition Rate of 2654 to 1... Highest in the Bio Industry
by Lee Seunghyeong
Published 26 Mar.2024 19:43(KST)
Margin Deposits Totaling 10.7827 Trillion Won Gathered
The liquid biopsy platform specialist IMBDX recorded a subscription competition rate of 2654.2 to 1 in its public offering for general investors, marking the highest competition rate among bio-listed companies.
The subscription deposit amounted to 10.7827 trillion KRW, with 465,671 applicants.
The funds secured through the listing will be used for research and development (R&D) and overseas expansion. Kim Tae-yu, co-founder of IMBDX and a professor of oncology at Seoul National University Hospital, said, "We thank all the investors who showed great interest even in the general subscription."
IMBDX will be listed on the KOSDAQ market on the 3rd of next month.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.